Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 5 May 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026. The programme is now concluded.
Since the announcement 27 April 2026, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 13,407,992 | 3,438,931,195 | |
| 27 April 2026 | 230,000 | 260.37 | 59,884,786 |
| 28 April 2026 | 230,000 | 263.34 | 60,567,237 |
| 29 April 2026 | 230,000 | 260.53 | 59,921,977 |
| 30 April 2026 | 230,000 | 264.07 | 60,735,091 |
| 1 May 2026 | 230,000 | 274.85 | 63,216,000 |
| 4 May 2026 | 201,187 | 282.04 | 56,743,704 |
| Accumulated under the programme | 14,759,179 | 3,799,999,990 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 32,148,978 B shares of DKK 0.10 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 4 May 2026, Novo Nordisk has since 4 February 2026 repurchased a total 14,759,179 B shares at an average share price of DKK 257.47 per B share equal to a transaction value of DKK 3,799,999,990.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 [email protected] | Liz Skrbkova (US) +1 609 917 0632 [email protected] |
| Investors: | |
| Michael Novod +45 3075 6050 [email protected] | Jacob Martin Wiborg Rode +45 3075 5956 [email protected] |
| Max Ung +45 3077 6414 [email protected] | Sina Meyer +45 3079 6656 [email protected] |
| Alex Bruce +45 34 44 26 13 [email protected] | Christoffer Sho Togo Tullin +45 3079 1471 [email protected] |
| Frederik Taylor Pitter +1 609 613 0568 [email protected] | Mads Berner Bruun +45 3075 2936 [email protected] |
Company announcement No 29 / 2026
Attachments
